The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study
The issue of a therapy of children with juvenile idiopathic arthritis (JIA) with intolerance or insufficient effectiveness of methotrexate remains actual.Objective: Our aim was to study the efficacy and safety of tocilizumab in patients with polyarticular JIA.Methods. In a retrospective study, we st...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2017-06-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/1746 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411721372893184 |
|---|---|
| author | Mikhail M. Kostik Irina A. Chikova Eugenia A. Isupova Margarita E. Dubko Vera V. Masalova Tatyana S. Likhacheva Ludmila S. Snegireva Ekaterina V. Gaidar Olga V. Kalashnikova Vyacheslav G. Chasnyk |
| author_facet | Mikhail M. Kostik Irina A. Chikova Eugenia A. Isupova Margarita E. Dubko Vera V. Masalova Tatyana S. Likhacheva Ludmila S. Snegireva Ekaterina V. Gaidar Olga V. Kalashnikova Vyacheslav G. Chasnyk |
| author_sort | Mikhail M. Kostik |
| collection | DOAJ |
| description | The issue of a therapy of children with juvenile idiopathic arthritis (JIA) with intolerance or insufficient effectiveness of methotrexate remains actual.Objective: Our aim was to study the efficacy and safety of tocilizumab in patients with polyarticular JIA.Methods. In a retrospective study, we studied the results of the use of tocilizumab in patients with active polyarticular JIA ( 5 active joints) resistant to prior therapy with methotrexate or a combination of methotrexate with other nonbiologic disease-modifying antiinflammatory drugs.Results. The data of 40 children (83% girls) with the onset median of polyarticular JIA of 4.8 (2.9, 8.1) years and the interval between the disease onset and the initiation of tocilizumab therapy of 5.7 (1.8, 8.5) years was analyzed. Tocilizumab was used as an intravenous infusion of 8 mg/kg (with a weight 30 kg) or 10 mg/kg (with a weight < 30 kg) every 4 weeks. The duration of tocilizumab monotherapy in 5 (13%) children was 1,109 days (452; 1,542). The stages of inactive disease (according to the criteria of C. Wallace, 2004) in 6 months of tocilizumab therapy reached 6 (15%) patients, in 42 months — 32 (80%) patients. In 3 patients, tocilizumab was canceled due to persistent remission. After 6 months of treatment, there was a marked decrease in erythrocyte sedimentation rate, C-reactive protein concentration, number of leukocytes and platelets (in all cases, p < 0.001) to normal values, which persisted throughout the whole period of drug administration. Predictors for achieving inactive disease were the initial (at the onset of tocilizumab therapy) number of peripheral blood leukocytes < 9.0X109/l [relative risk (RR) 1.92; 95% confidence interval (CI) 0.9–4.6)] and the absence of prior biological therapy (RR 1.92, 95% CI 0.9–4.6). The most frequent side effects of tocilizumab therapy were transient hypercholesterolemia (in 13), hypertriglyceridemia (in 4), transient grade II neutropenia (in 1).Conclusion. The long-term efficacy and relative safety of tocilizumab in children with polyarticular JIA have been showed. |
| format | Article |
| id | doaj-art-6a94561c6b8e4bdc8fd48f69f4578e93 |
| institution | Kabale University |
| issn | 1682-5527 1682-5535 |
| language | English |
| publishDate | 2017-06-01 |
| publisher | "Paediatrician" Publishers LLC |
| record_format | Article |
| series | Вопросы современной педиатрии |
| spelling | doaj-art-6a94561c6b8e4bdc8fd48f69f4578e932025-08-20T03:34:41Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352017-06-0116214815510.15690/vsp.v16i2.17161674The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective StudyMikhail M. Kostik0Irina A. Chikova1Eugenia A. Isupova2Margarita E. Dubko3Vera V. Masalova4Tatyana S. Likhacheva5Ludmila S. Snegireva6Ekaterina V. Gaidar7Olga V. Kalashnikova8Vyacheslav G. Chasnyk9St. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversitySt. Petersburg State Pediatric Medical UniversityThe issue of a therapy of children with juvenile idiopathic arthritis (JIA) with intolerance or insufficient effectiveness of methotrexate remains actual.Objective: Our aim was to study the efficacy and safety of tocilizumab in patients with polyarticular JIA.Methods. In a retrospective study, we studied the results of the use of tocilizumab in patients with active polyarticular JIA ( 5 active joints) resistant to prior therapy with methotrexate or a combination of methotrexate with other nonbiologic disease-modifying antiinflammatory drugs.Results. The data of 40 children (83% girls) with the onset median of polyarticular JIA of 4.8 (2.9, 8.1) years and the interval between the disease onset and the initiation of tocilizumab therapy of 5.7 (1.8, 8.5) years was analyzed. Tocilizumab was used as an intravenous infusion of 8 mg/kg (with a weight 30 kg) or 10 mg/kg (with a weight < 30 kg) every 4 weeks. The duration of tocilizumab monotherapy in 5 (13%) children was 1,109 days (452; 1,542). The stages of inactive disease (according to the criteria of C. Wallace, 2004) in 6 months of tocilizumab therapy reached 6 (15%) patients, in 42 months — 32 (80%) patients. In 3 patients, tocilizumab was canceled due to persistent remission. After 6 months of treatment, there was a marked decrease in erythrocyte sedimentation rate, C-reactive protein concentration, number of leukocytes and platelets (in all cases, p < 0.001) to normal values, which persisted throughout the whole period of drug administration. Predictors for achieving inactive disease were the initial (at the onset of tocilizumab therapy) number of peripheral blood leukocytes < 9.0X109/l [relative risk (RR) 1.92; 95% confidence interval (CI) 0.9–4.6)] and the absence of prior biological therapy (RR 1.92, 95% CI 0.9–4.6). The most frequent side effects of tocilizumab therapy were transient hypercholesterolemia (in 13), hypertriglyceridemia (in 4), transient grade II neutropenia (in 1).Conclusion. The long-term efficacy and relative safety of tocilizumab in children with polyarticular JIA have been showed.https://vsp.spr-journal.ru/jour/article/view/1746childrenpolyarticular juvenile idiopathic arthritistocilizumabinterleukin 6 |
| spellingShingle | Mikhail M. Kostik Irina A. Chikova Eugenia A. Isupova Margarita E. Dubko Vera V. Masalova Tatyana S. Likhacheva Ludmila S. Snegireva Ekaterina V. Gaidar Olga V. Kalashnikova Vyacheslav G. Chasnyk The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study Вопросы современной педиатрии children polyarticular juvenile idiopathic arthritis tocilizumab interleukin 6 |
| title | The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study |
| title_full | The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study |
| title_fullStr | The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study |
| title_full_unstemmed | The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study |
| title_short | The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study |
| title_sort | use of tocilizumab in 40 patients with polyarticular juvenile idiopathic arthritis the results of a retrospective study |
| topic | children polyarticular juvenile idiopathic arthritis tocilizumab interleukin 6 |
| url | https://vsp.spr-journal.ru/jour/article/view/1746 |
| work_keys_str_mv | AT mikhailmkostik theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT irinaachikova theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT eugeniaaisupova theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT margaritaedubko theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT veravmasalova theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT tatyanaslikhacheva theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT ludmilassnegireva theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT ekaterinavgaidar theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT olgavkalashnikova theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT vyacheslavgchasnyk theuseoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT mikhailmkostik useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT irinaachikova useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT eugeniaaisupova useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT margaritaedubko useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT veravmasalova useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT tatyanaslikhacheva useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT ludmilassnegireva useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT ekaterinavgaidar useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT olgavkalashnikova useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy AT vyacheslavgchasnyk useoftocilizumabin40patientswithpolyarticularjuvenileidiopathicarthritistheresultsofaretrospectivestudy |